Cargando…

Combination microRNA-based cellular reprogramming with paclitaxel enhances therapeutic efficacy in a relapsed and multidrug-resistant model of epithelial ovarian cancer

Most advanced-stage ovarian cancer patients, including those with epithelial ovarian cancer (EOC), develop recurrent disease and acquisition of resistance to chemotherapy, leading to limited treatment options. Decrease in Let7b miRNA levels in clinical ovarian cancer has been associated with chemore...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gandham, Srujan K., Rao, Mounika, Shah, Aayushi, Trivedi, Malav S., Amiji, Mansoor M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971728/ https://www.ncbi.nlm.nih.gov/pubmed/35399604 http://dx.doi.org/10.1016/j.omto.2022.03.005

Ejemplares similares

Inhibition of hexokinase-2 with targeted liposomal 3-bromopyruvate in an ovarian tumor spheroid model of aerobic glycolysis
por: Gandham, Srujan Kumar, et al.
Publicado: (2015)

MicroRNA-34a Encapsulated in Hyaluronic Acid Nanoparticles Induces Epigenetic Changes with Altered Mitochondrial Bioenergetics and Apoptosis in Non-Small-Cell Lung Cancer Cells
por: Trivedi, Malav, et al.
Publicado: (2017)

Pancreatic Cancer Cell Exosome-Mediated Macrophage Reprogramming and the Role of MicroRNAs 155 and 125b2 Transfection using Nanoparticle Delivery Systems
por: Su, Mei-Ju, et al.
Publicado: (2016)

Technologies and Standardization in Research on Extracellular Vesicles
por: Gandham, Srujan, et al.
Publicado: (2020)

Therapeutic Efficacy and Safety of Paclitaxel/Lonidamine Loaded EGFR-Targeted Nanoparticles for the Treatment of Multi-Drug Resistant Cancer
por: Milane, Lara, et al.
Publicado: (2011)

MDR1 siRNA loaded hyaluronic acid-based CD44 targeted nanoparticle systems circumvent paclitaxel resistance in ovarian cancer
por: Yang, Xiaoqian, et al.
Publicado: (2015)

Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience.
por: Gore, M. E., et al.
Publicado: (1995)

Cellular Reprogramming Using Defined Factors and MicroRNAs
por: Eguchi, Takanori, et al.
Publicado: (2016)

Biodistribution and Pharmacokinetic Analysis of Paclitaxel and Ceramide Administered in Multifunctional Polymer-Blend Nanoparticles in Drug Resistant Breast Cancer Model
por: van Vlerken, Lilian E., et al.
Publicado: (2008)

Proteomic and Phosphoproteomic Reprogramming in Epithelial Ovarian Cancer Metastasis
por: Frederick, Mallory I., et al.
Publicado: (2023)

MicroRNA-223 Induced Repolarization of Peritoneal Macrophages Using CD44 Targeting Hyaluronic Acid Nanoparticles for Anti-Inflammatory Effects
por: Tran, Thanh-Huyen, et al.
Publicado: (2016)

Overexpression of the microRNA miR-433 promotes resistance to paclitaxel through the induction of cellular senescence in ovarian cancer cells
por: Weiner-Gorzel, Karolina, et al.
Publicado: (2015)

MyD88 predicts chemoresistance to paclitaxel in epithelial ovarian cancer
por: Silasi, Dan-Arin, et al.
Publicado: (2007)

A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer.
por: Siddiqui, N., et al.
Publicado: (1997)

Characterization of tumour microenvironment reprogramming reveals invasion in epithelial ovarian carcinoma
por: Zhang, Yuanfu, et al.
Publicado: (2023)

Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial–mesenchymal transition interlinked with reprogrammed metabolism
por: Leung, Dilys, et al.
Publicado: (2022)

Modification of tumor cell exosome content by transfection with wt-p53 and microRNA-125b expressing plasmid DNA and its effect on macrophage polarization
por: Trivedi, M, et al.
Publicado: (2016)

Phase II study of intraperitoneal submicron particle paclitaxel (SPP) plus IV carboplatin and paclitaxel in patients with epithelial ovarian cancersurgery
por: Mullany, Sally, et al.
Publicado: (2020)

Paclitaxel is necessary for improved survival in epithelial ovarian cancers with homologous recombination gene mutations
por: Jean, Stephanie, et al.
Publicado: (2016)

Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer
por: Gao, Bo, et al.
Publicado: (2018)

NIPEC with Single-Dose Intraperitoneal Cisplatin and Paclitaxel in Stage III Epithelial Ovarian Cancer
por: Saldanha, Elroy, et al.
Publicado: (2022)

Metabolic Reprogramming During Multidrug Resistance in Leukemias
por: Vidal, Raphael Silveira, et al.
Publicado: (2018)

Nanoparticulate carriers for the treatment of coronary restenosis
por: Brito, Luis, et al.
Publicado: (2007)

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
por: Xu, Jing, et al.
Publicado: (2012)

Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine
por: Milane, Lara, et al.
Publicado: (2021)

Expanding CRISPR repertoire using CjCas9 as a smaller editing tool
por: Francis, Christopher, et al.
Publicado: (2022)

Algorithm for cellular reprogramming
por: Ronquist, Scott, et al.
Publicado: (2017)

Weekly Paclitaxel Versus Three-Weekly Paclitaxel in Recurrent Platinum-Resistant Epithelial Ovarian and Peritoneal Cancers: A Phase III Study
por: Osman, Mohammed A., et al.
Publicado: (2016)

MicroRNA characteristics in epithelial ovarian cancer
por: Prahm, Kira Philipsen, et al.
Publicado: (2021)

Redox-based epigenetic status in drug addiction: a potential contributor to gene priming and a mechanistic rationale for metabolic intervention
por: Trivedi, Malav S., et al.
Publicado: (2015)

Embryonic MicroRNA-369 Controls Metabolic Splicing Factors and Urges Cellular Reprograming
por: Konno, Masamitsu, et al.
Publicado: (2015)

Incomplete cellular reprogramming of colorectal cancer cells elicits an epithelial/mesenchymal hybrid phenotype
por: Hiew, Michele Sook Yuin, et al.
Publicado: (2018)

Role of MicroRNA in Inflammatory Bowel Disease: Clinical Evidence and the Development of Preclinical Animal Models
por: Suri, Kanika, et al.
Publicado: (2021)

Methylation-associated Has-miR-9 deregulation in paclitaxel- resistant epithelial ovarian carcinoma
por: Li, Xiao, et al.
Publicado: (2015)

Proton pump inhibitors can reverse the YAP mediated paclitaxel resistance in epithelial ovarian cancer
por: He, Jing, et al.
Publicado: (2019)

Dual TNF-α/Cyclin D1 Gene Silencing With an Oral Polymeric Microparticle System as a Novel Strategy for the Treatment of Inflammatory Bowel Disease
por: Kriegel, Christina, et al.
Publicado: (2011)

Molecular Imaging of Subclinical Diabetic Retinopathy
por: Russmann, Christoph, et al.
Publicado: (2017)

Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts
por: Ricci, Francesca, et al.
Publicado: (2017)

Corrigendum: Metabolic Reprogramming During Multidrug Resistance in Leukemias
por: Vidal, Raphael Silveira, et al.
Publicado: (2018)

Transcriptional reprogramming in cellular quiescence
por: Roche, Benjamin, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_uqnf7ol19hge69ipbvlev2eufe